Literature DB >> 28981152

Low conversion rate of ocular to generalized myasthenia gravis in Singapore.

Kelvin Y Teo1, Sharon L Tow2, Benjamin Haaland3, Tushar D Gosavi4, Loo Jing-Liang5, L O Yew Long4, Dan Milea2.   

Abstract

INTRODUCTION: Ocular myasthenia gravis (OMG) is a common condition of the neuromuscular junction that may convert to generalized myasthenia gravis (GMG). Our aim in this study was to determine the conversion rate and predictive factors for generalization in OMG, in an Asian population.
METHODS: The investigation consisted of a retrospective study of OMG patients with a minimum 2 years of follow-up.
RESULTS: Among 191 patients with OMG, 155 had the minimum 2-year follow-up. The conversion rate at median follow-up (40.8 months) was 10.6% (95% confidence interval 7.9%-13.3%), and at the 2-year follow-up it was 7.7% (95% confidence interval 5.6%-9.8%). At baseline, the predictive factors for generalization were positive acetylcholine receptor antibodies (hazard ratio 3.71, P = 0.024), positive repetitive nerve stimulation (RNS) studies (hazard ratio 4.42, P = 0.003), and presence of radiologically presumed or pathologically confirmed thymoma (hazard ratio 3.10, P = 0.013). DISCUSSION: The conversion rate of OMG to GMG in Asian patients is low, as predicted by presence of acetylcholine receptor antibodies, presence of thymoma, and positive RNS studies. Muscle Nerve 57: 756-760, 2018.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  acetylcholine receptor antibodies; diplopia; generalization; myasthenia gravis; ocular myasthenia gravis; ptosis

Mesh:

Substances:

Year:  2017        PMID: 28981152     DOI: 10.1002/mus.25983

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  8 in total

1.  Prediction of the generalization of myasthenia gravis with purely ocular symptoms at onset: a multivariable model development and validation.

Authors:  Feng Li; Hongbin Zhang; Ya Tao; Frauke Stascheit; Jiaojiao Han; Feng Gao; Hongbo Liu; Alberto Carmona-Bayonas; Zhongmin Li; Jens-C Rueckert; Andreas Meisel; Song Zhao
Journal:  Ther Adv Neurol Disord       Date:  2022-06-21       Impact factor: 6.430

2.  Generalization after ocular onset in myasthenia gravis: a case series in Germany.

Authors:  Feng Li; Benjamin Hotter; Marc Swierzy; Mahmoud Ismail; Andreas Meisel; Jens-C Rückert
Journal:  J Neurol       Date:  2018-09-17       Impact factor: 4.849

3.  Ophthalmologic manifestations in myasthenia gravis: presentation and prognosis.

Authors:  Onur Akan; Leyla Baysal-Kirac
Journal:  Acta Neurol Belg       Date:  2021-01-04       Impact factor: 2.396

4.  Prognostic factors for conversion to generalization in ocular myasthenia gravis.

Authors:  Juthamat Witthayaweerasak; Narisa Rattanalert; Nipat Aui-Aree
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

5.  Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China.

Authors:  Xin Huang; Yingkai Li; Huiyu Feng; Pei Chen; Weibin Liu
Journal:  Front Neurol       Date:  2018-02-27       Impact factor: 4.003

Review 6.  Controversies in Ocular Myasthenia Gravis.

Authors:  Amelia Evoli; Raffaele Iorio
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

7.  Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis.

Authors:  Mingxia Li; Fangfang Ge; Rongjing Guo; Zhe Ruan; Yanwu Gao; Chunxiao Niu; Hong Lin; Zhengwei Zhao; Yongan Zhou; Zhuyi Li; Ting Chang
Journal:  Ther Adv Neurol Disord       Date:  2019-09-14       Impact factor: 6.570

8.  Development and Validation of a Nomogram for Predicting Generalization in Patients With Ocular Myasthenia Gravis.

Authors:  Zhe Ruan; Chao Sun; Yanlin Lang; Feng Gao; Rongjing Guo; Quan Xu; Liping Yu; Songdi Wu; Tao Lei; Yu Liu; Min Zhang; Huanhuan Li; Yonglan Tang; Ting Gao; Yanwu Gao; Xiaodan Lu; Zhuyi Li; Ting Chang
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.